Remote monitoring with the Reveal Linq insertable cardiac monitor can improve outcomes without breaking the bank, according to new data being presented at the International Stroke Conference in Phoenix.

The company, part of Johnson & Johnson MedTech, shared positive data from two different clinical trials at AF Symposium 2024 in Boston.

Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.

Medtronic is celebrating the success of its PulseSelect pulsed field ablation product by highlighting its impact on heart patients around the world. 

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Injuries to the esophagus remain a common complication associated with radiofrequency ablation procedures. New research suggests a device developed by S4 Medical could significantly reduce the risk of such injuries. 

The device, which also received Great Britain’s UKCA marking, was specifically designed to be less bulky and easier to wear than other wearable cardioverter-defibrillators.

Performing two procedures at once does not appear to make a significant impact on patient safety, though it may lead to a few new risks sure to interest heart teams.